Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict the asset could beat out AbbVie’s Skyrizi and generate sales of up to $10 billion. The biotech’s share price opened up 30% at $89.50.